FGEN FibroGen Inc.

FibroGen to Report Second Quarter 2022 Financial Results

FibroGen to Report Second Quarter 2022 Financial Results

SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast

Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at . To access the call by phone, please go to this link (), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link ().

About FibroGen

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit

Contacts: FibroGen, Inc.

Investors:

Michael Tung, M.D.

Corporate Strategy / Investor Relations

1.415.978.1434

Media:

Meichiel Keenan

Investor Relations and Corporate Communications

 



EN
25/07/2022

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Announces 1-for-25 Reverse Stock Split SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen’s common stock will begin trading on a split-adjusted basis on June 17, 2025, when the markets open, under the Company’s existing trading symbol “FGEN,” with the new CUSIP number 31572Q881. The Reverse Stock Split was previously approved by stockholders at the Compa...

June 12, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Direct...

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. “Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board,” said James Schoeneck, chairman of the board of directors of FibroGen. “His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael’s deep understanding o...

June 9, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Reports First Quarter 2025 Financial Results and Provides Bus...

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2H 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-r...

May 12, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Report First Quarter 2025 Financial Results SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. ...

May 5, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare ...

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. FibroGen’s management team will be available for one-on-one meetings on Wednesday, April 9th. Interested investors should contact their representative at Needham. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer bi...

April 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch